Identifying Barriers and Facilitators to Scalp Cooling Therapy Through a National Survey of the Awareness, Practice Patterns, and Attitudes of Oncologists
- 1 February 2022
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 18 (2) , e225-e234
Abstract
PURPOSE: Scalp cooling therapy (SCT) is the most effective method to reduce chemotherapy-induced alopecia (CIA), a highly distressing side effect of cancer treatment. Despite data supporting SCT efficacy and safety, SCT use in the United States is not widespread. Oncologists' interactions with scalp cooling were examined to identify facilitators and barriers to SCT implementation. METHODS: A 33-question survey was distributed through the ASCO Research Survey Pool to a nationally representative, random sample of 600 oncology providers. Outcome measures included knowledge of SCT, frequency of initiating conversations about SCT with patients, degree of support, and barriers for SCT. Significance was defined as P < .001. RESULTS: Of 155 (25.8%) responding providers, 62% of providers were in favor of SCT always or most of the time, but only 26% reported initiating discussions about SCT always or most of the time. Providers who treat breast cancer ( P ≤ .0001), those who report being very familiar with SCT ( P ≤ .0001), those who report having read SCT literature in the past 2 years ( P ≤ .0001), and those who work at a facility with machine SCT ( P ≤ .0001) were significantly more likely to initiate conversations with patients about SCT. Financial concerns (58%) were the primary reason for not recommending SCT use; efficacy (31%), staff or facility (24%), and safety (15%) concerns were also noted. Although safety concerns have decreased markedly over time, 14% of providers report patients who continue to express these concerns and 17% of providers see safety issues as barriers to supporting SCT. CONCLUSION: Our findings suggest that oncology provider familiarity and experience with SCT lead to increased support for scalp cooling, which may ultimately result in greater availability and utilization of SCT when indicated.Keywords
This publication has 39 references indexed in Scilit:
- Scalp cooling to prevent alopecia after chemotherapy can be considered safe in patients with breast cancerThe Breast, 2013
- Factors Influencing the Effectiveness of Scalp Cooling in the Prevention of Chemotherapy-Induced AlopeciaThe Oncologist, 2013
- Scalp cooling for hair preservation and associated characteristics in 1411 chemotherapy patients - Results of the Dutch Scalp Cooling RegistryActa Oncologica, 2012
- Results from the survey for preservation of adolescent reproduction (SPARE) study: gender disparity in delivery of fertility preservation message to adolescents with cancerJournal of Assisted Reproduction and Genetics, 2010
- Incidence of scalp metastases in breast cancer: a retrospective cohort study in women who were offered scalp coolingBreast Cancer Research and Treatment, 2009
- Have men been overlooked? A comparison of young men and women's experiences of chemotherapy‐induced alopeciaPsycho-Oncology, 2007
- Effectiveness of cold cap in the prevention of docetaxel-induced alopeciaEuropean Journal of Cancer, 1997
- The symptom experience of alopeciaSeminars in Oncology Nursing, 1995
- Chemotherapy-Induced AlopeciaSouthern Medical Journal, 1993
- Preventing chemotherapy‐induced alopecia in cancer patients: is scalp cooling worthwhile?Journal of Advanced Nursing, 1987